tositumomab + iodine-131 tositumomab

Tositumomab + iodine-131 tositumomab is a combination drug regimen used primarily for the treatment of CD20-positive, relapsed or refractory non-Hodgkin's lymphoma. The therapy consists of two components: tositumomab, a murine IgG2a lambda monoclonal antibody that targets the CD20 antigen on B-cells, and iodine I 131-labeled tositumomab, which delivers targeted radiation to these cells. The mechanism of action involves both immune-mediated cytotoxicity through binding to CD20 on malignant B-cells and direct cell killing via ionizing radiation emitted by the radioactive isotope. This dual approach aims to maximize cancer cell destruction in patients whose disease has not responded to prior therapies such as rituximab and chemotherapy[1][5][7].

Brand names

Bexxar

Other names

iodine I 131 tositumomabAnti-CD20 murine monoclonal antibody-I-131Anti-CD-20 murine monoclonal antibody-I-131Anti-CD 20 murine monoclonal antibody-I-131B1B-1B 1Iodine 131 tositumomabIodine131 tositumomabIodine-131 tositumomabIodine-131 anti-B1 antibodyIodine131 anti-B1 antibodyIodine 131 anti-B1 antibody